NCT04999267

Brief Summary

The benefits of adolescent vaccines are well known for preventing meningococcal infection and human papillomavirus (HPV)-related pre-cancerous lesions. Yet, many adolescents in the United States (US) remain under-vaccinated, with vaccination rates among rural adolescents significantly lower than among their urban peers. In addition, there are urban-rural disparities in the coverage of HPV vaccine, particularly in Southern states like North and South Carolina, which currently fall below the Healthy People 2020 goal of ≥80% coverage. The goal of the proposed study is to evaluate the feasibility and preliminary efficacy of a school-based intervention for increasing vaccine uptake among adolescents in rural North and South Carolina.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2021

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 5, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 10, 2021

Completed
21 days until next milestone

Study Start

First participant enrolled

August 31, 2021

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 3, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 3, 2022

Completed
2.1 years until next milestone

Results Posted

Study results publicly available

December 4, 2024

Completed
Last Updated

December 10, 2025

Status Verified

November 1, 2025

Enrollment Period

1.2 years

First QC Date

August 5, 2021

Results QC Date

October 11, 2023

Last Update Submit

November 24, 2025

Conditions

Keywords

Human papillomavirus (HPV)AdolescentSchool based interventionVaccineHPV vaccine

Outcome Measures

Primary Outcomes (1)

  • Difference in the Percentage of Adolescents Who Ever Received at Least One Dose of HPV Vaccination in the Intervention Group After the Intervention Implementation Compared With Before Intervention Implementation

    HPV vaccination status (received at least one versus no doses) of middle schoolers (by district) will be obtained from official vaccination records before and after intervention implementation.

    Baseline, 9 months

Secondary Outcomes (2)

  • Difference in Percentage of Adolescents Who Have Completed the HPV Vaccination Series (2 Doses Depending on Age at Vaccination Initiation) in the Intervention Group After Implementation Compared With Before Intervention Implementation

    Baseline, 9 months

  • Fidelity of Intervention Across Intervention Schools

    9 months

Study Arms (1)

INVEST Intervention School Districts

EXPERIMENTAL
Other: INVEST

Interventions

INVESTOTHER

The intervention will consist of 3 primary components: 1) school nurse training and technical support for promoting adolescent vaccination (Tdap, MenACWY, HPV) and strengthening existing school nursing vaccination programming, 2) caregiver-targeted educational materials that are disseminated via school nurses, and 3) tools and resources to facilitate linkage to vaccination providers in the local community. Existing materials will be used in the intervention such as resources available from the Centers for Disease Control and Prevention and Middle School Health Starts Here tool kit from the National Association of School Nurses and the National HPV Roundtable. Technical support includes the study team working with local school nurses to identify educational materials available from national and statewide sources.

INVEST Intervention School Districts

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • \- Any public middle school in Cherokee County, South Carolina or Rockingham County, North Carolina school districts

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Duke University

Durham, North Carolina, 29340, United States

Location

University of South Carolina

Columbia, South Carolina, 29208, United States

Location

MeSH Terms

Conditions

Vaccination Hesitancy

Condition Hierarchy (Ancestors)

Vaccination RefusalTreatment RefusalTreatment Adherence and ComplianceHealth BehaviorBehavior

Results Point of Contact

Title
Chip Walter
Organization
Duke University - Duke Human Vaccine Institute

Study Officials

  • Emmanuel Walter, MD, MPH

    Duke University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 5, 2021

First Posted

August 10, 2021

Study Start

August 31, 2021

Primary Completion

November 3, 2022

Study Completion

November 3, 2022

Last Updated

December 10, 2025

Results First Posted

December 4, 2024

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations